Chiesi Wins FDA Approval for First Drug to Treat Ultra-Rare Enzyme Deficiency
Chiesi drug Lamzede is an engineered version of an enzyme that’s lacking in patients with the rare disease alpha-mannosidosis. FDA approval of the Chiesi drug comes about five years after European regulators authorized the product.
Information Courtesy By: Frank Vinluan, #HealthcareNews #Healthcare | Feeds
Chiesi drug Lamzede is an engineered version of an enzyme that’s lacking in patients with the rare disease alpha-mannosidosis. FDA approval of the Chiesi drug comes about five years after European regulators authorized the product.
Click For More Details
2023-02-17 23:43
Except for the headline, this story has not been edited by Healthcare Central is published from a syndicated feed.